UNDERWRITING AGREEMENT Aligos Therapeutics, Inc. [●] Shares of Common StockUnderwriting Agreement • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of ________ __, 20__ by and between Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 9th day of October, 2020, by and among Aligos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
May 14, 2019 ALIGOS THERAPEUTICS, INC. Lucinda Y. Quan [Address]Confirmatory Employment Letter • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This letter agreement (“Agreement”) is entered into between Lucinda Y. Quan (“you”) and Aligos Therapeutics, Inc. (the “Company” or “we”), effective as of October 16, 2018 (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
EMPLOYMENT AGREEMENTEmployment Agreement • October 9th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is entered into effective as of August 16, 2018 (the “Effective Date”), by and between Aligos Therapeutics, Inc., a Delaware corporation (the “Company”) and Lawrence M. Blatt, Ph.D. (the “Executive”).
